THERAPY DOSSIER · th-9b1df9f39108

miR-210-LNA (locked nucleic acid inhibitor of microRNA-210)

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29111308 ↗2017Reported benefit

Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6Malen = 85 mice purchased with 11 added for dropouts, 96 used overa…Intracerebroventricular injection into the left lateral ventricle100 pmol in 4 ul24 h before MCAO (pretreatment) or 4 h after MCAO (post-treatment)

Model: Focal cerebral ischaemia by intraluminal middle cerebral artery occlusion for 60 min followed by reperfusion, under 1.5% isoflurane with body temperature at 37 +/- 0.5 degrees C

Pretreatment with miR-210-LNA abolished the ischaemia-induced rise in brain miR-210 and reduced infarct volume (30.6 +/- 1.5% versus 49.2 +/- 2.9%, p < 0.01) and oedema, with improved neurological score and foot-fault performance. It suppressed TNF-alpha, IL-1beta, IL-6, CCL2 and CCL3 and reduced m…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…